Advanced Search: Metastatic

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201912097

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors

202001128

A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors

202006133

A phase 1b dose escalation study of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy for HER2+ gastrointestinal cancers

202105140

Phase 1/1B study of DS-8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial)

202104080

A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of thorium-227 labeled antibody-chelator conjugate BAY 2701439, in participants with advanced HER2-expressing tumors

202105147

Phase 1/1b Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers

202201030

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936-0901 (Anti-ADAM9 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors

202012018

Phase II study of short course FOLFOX chemotherapy with either Nivolumab or Nivolumab + Radiation in the first line treatment of metastatic or unresectable gastroesophageal cancers (BMS Protocol CA209-76L)